Synthorx (THOR) Stock Price, News & Analysis

Company Overview

Synthorx, Inc., a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor. It also develops IL-2 Synthorin for autoimmune indications; IL-10 Synthorin, a naturally occurring immune cell growth factor in humans for the treatment of immuno-oncology (IO); and IL-15 Synthorins, an immunoregulatory cytokine to treat IO. In addition, the company develops other Synthorin programs targeting undisclosed cytokines that play critical roles in the orchestration of anti-tumor responses by innate and adaptive immune cells. The company was formerly known as Alinos, Inc. and changed its name to Synthorx, Inc. in March 2014. Synthorx, Inc. was founded in 2014 and is headquartered in La Jolla, California.

Key Stats

• Today's Range: $67.99 to $67.99
• 50-Day Range: $67.99 to $67.99
• 52-Week Range: $11.05 to $71.90
• Volume: N/A
• Average Volume: 474,507 shs
• Market Capitalization: $2.20 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

THOR Stock Analysis - Frequently Asked Questions

How were Synthorx's earnings last quarter?

Synthorx, Inc. (NASDAQ:THOR) released its quarterly earnings data on Tuesday, November, 5th. The medical instruments supplier reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.12.

When did Synthorx IPO?

Synthorx (THOR) raised $100 million in an IPO on Friday, December 7th 2018. The company issued 9,100,000 shares at $10.00-$12.00 per share. Jefferies, Leerink Partners and Evercore ISI served as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.

What other stocks do shareholders of Synthorx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Synthorx investors own include Pfizer (PFE), NVIDIA (NVDA), Gilead Sciences (GILD), Meta Platforms (META), Alibaba Group (BABA), Tesla (TSLA) and Salesforce (CRM).

Company Calendar

• Last Earnings: 11/05/2019
• Today: 1/05/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Health Care Equipment
• Current Symbol: NASDAQ:THOR
• CUSIP: 88517530
• CIK: 350907
• Web: www.synthorx.com
• Phone: 858-750-4700
• Fax: N/A
• Employees: 48
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($6.59)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-56,610,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -26.09%
• Return on Assets: -24.62%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 18.87
• Quick Ratio: 18.87

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.72 per share
• Price / Book: 10.12

Miscellaneous

• Outstanding Shares: 32,338,000
• Free Float: N/A
• Market Cap: $2.20 billion
• Optionable: Not Optionable
• Beta: N/A